Table 2.
FOLFOX Dose Reduction and Discontinuation by Treatment Arm
| Variable | CaMg Before and After Chemotherapy (n = 118) |
Placebo (n = 119) |
CaMg Before and Placebo After Chemotherapy (n = 116) |
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | % | Mean | SD | Median | Q1, Q3 | Range | P | No. | % | Mean | SD | Median | Q1, Q3 | Range | No. | % | Mean | SD | Median | Q1, Q3 | Range | P | |
| No. of cycles | 117 | 9.5 | 3.2 | 11.0 | 8.0, 12.0 | 1.0-12.0 | .8077* | 116 | 9.2 | 3.4 | 11.0 | 6.5, 12.0 | 1.0-12.0 | 115 | 9.9 | 2.9 | 12.0 | 8.0, 12.0 | 1.0-12.0 | .1941* | |||
| Dose reduction | .9462† | .9491† | |||||||||||||||||||||
| Missing | 1 | 3 | 1 | ||||||||||||||||||||
| Yes | 60 | 51.3 | 60 | 51.7 | 59 | 51.3 | |||||||||||||||||
| No | 57 | 48.7 | 56 | 48.3 | 56 | 48.7 | |||||||||||||||||
| Dose reduction cycle | 60 | 5.7 | 2.7 | 5.0 | 3.5, 8.0 | 2.0-12.0 | .3749* | 60 | 6.2 | 2.9 | 6.0 | 3.5, 9.0 | 2.0-12.0 | 59 | 6.6 | 3.2 | 6.0 | 4.0, 9.0 | 2.0-12.0 | .5637* | |||
| Discontinued | .5223† | .6637† | |||||||||||||||||||||
| Missing | 17 | 14 | 15 | ||||||||||||||||||||
| Yes | 35 | 34.7 | 32 | 30.5 | 28 | 27.7 | |||||||||||||||||
| No | 66 | 65.3 | 73 | 69.5 | 73 | 72.3 | |||||||||||||||||
| Cycle discontinued | 34 | 8.1 | 3.0 | 9.0 | 6.0, 11.0 | 1.0-12.0 | .8917* | 32 | 8.4 | 2.5 | 9.0 | 6.5, 10.0 | 2.0-12.0 | 28 | 8.0 | 2.6 | 8.0 | 6.0, 10.0 | 3.0-12.0 | .4960* | |||
Abbreviations: CaMg, calcium and magnesium; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; Q1, quartile 1; SD, standard deviation.
*
Kruskal-Wallis test.
†
χ2 test.